Arkolith/Insider Trading/MRSN/Form 4

Mandelia Ashish

VP, Chief Accounting OfficerMersana Therapeutics, Inc. (MRSN) · full profile →Form 4 · filed Jan 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
18
1 non-derivative · 17 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 6, 2026Tender(U)2K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 6, 2026Disposed to issuer(D)3K——0
Jan 6, 2026Disposed to issuer(D)1K——0
Jan 6, 2026Disposed to issuer(D)44——0
Jan 6, 2026Disposed to issuer(D)310——0
Jan 6, 2026Disposed to issuer(D)773——0
Jan 6, 2026Disposed to issuer(D)359——0
Jan 6, 2026Disposed to issuer(D)788——0
Jan 6, 2026Disposed to issuer(D)722——0
Jan 6, 2026Disposed to issuer(D)1K——0
Jan 6, 2026Disposed to issuer(D)1K——0
Jan 6, 2026Disposed to issuer(D)2K——0
Jan 6, 2026Disposed to issuer(D)192——0
Jan 6, 2026Disposed to issuer(D)212——0
Jan 6, 2026Disposed to issuer(D)500——0
Jan 6, 2026Disposed to issuer(D)666——0
Jan 6, 2026Disposed to issuer(D)555——0
Jan 6, 2026Disposed to issuer(D)2K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-001375) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML